annual CFF:
$139.42M-$79.33M(-36.26%)Summary
- As of today (July 1, 2025), TVTX annual cash flow from financing activities is $139.42 million, with the most recent change of -$79.33 million (-36.26%) on December 31, 2024.
- During the last 3 years, TVTX annual CFF has fallen by -$92.26 million (-39.82%).
- TVTX annual CFF is now -39.87% below its all-time high of $231.86 million, reached on December 31, 2018.
Performance
TVTX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$3.72M-$135.40M(-97.33%)Summary
- As of today (July 1, 2025), TVTX quarterly cash flow from financing activities is $3.72 million, with the most recent change of -$135.40 million (-97.33%) on March 31, 2025.
- Over the past year, TVTX quarterly CFF has increased by +$4.24 million (+808.19%).
- TVTX quarterly CFF is now -98.39% below its all-time high of $230.96 million, reached on September 30, 2018.
Performance
TVTX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$143.66M+$4.24M(+3.04%)Summary
- As of today (July 1, 2025), TVTX TTM cash flow from financing activities is $143.66 million, with the most recent change of +$4.24 million (+3.04%) on March 31, 2025.
- Over the past year, TVTX TTM CFF has increased by +$142.43 million (+11570.59%).
- TVTX TTM CFF is now -56.36% below its all-time high of $329.24 million, reached on March 31, 2021.
Performance
TVTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TVTX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -36.3% | +808.2% | +10000.0% |
| 3 y3 years | -39.8% | -96.7% | -4.1% |
| 5 y5 years | +6812.7% | +164.4% | +40.3% |
TVTX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -39.8% | +18.6% | -98.3% | +686.4% | -35.3% | >+9999.0% |
| 5 y | 5-year | -39.8% | +6812.7% | -98.3% | +686.4% | -56.4% | >+9999.0% |
| alltime | all time | -39.9% | +3722.3% | -98.4% | +109.3% | -56.4% | +444.3% |
TVTX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $3.72M(-97.3%) | $143.66M(+3.0%) |
| Dec 2024 | $139.42M(-36.3%) | $139.12M(>+9900.0%) | $139.42M(>+9900.0%) |
| Sep 2024 | - | $46.00K(-94.1%) | $427.00K(-268.8%) |
| Jun 2024 | - | $782.00K(-249.0%) | -$253.00K(-120.6%) |
| Mar 2024 | - | -$525.00K(-523.4%) | $1.23M(-99.4%) |
| Dec 2023 | $218.75M(+86.1%) | $124.00K(-119.6%) | $218.75M(-0.2%) |
| Sep 2023 | - | -$634.00K(-128.0%) | $219.18M(-1.3%) |
| Jun 2023 | - | $2.27M(-99.0%) | $222.09M(+0.7%) |
| Mar 2023 | - | $217.00M(>+9900.0%) | $220.66M(+87.7%) |
| Dec 2022 | $117.57M(-49.3%) | $551.00K(-75.8%) | $117.57M(-21.7%) |
| Sep 2022 | - | $2.28M(+174.1%) | $150.24M(-0.1%) |
| Jun 2022 | - | $831.00K(-99.3%) | $150.37M(+0.4%) |
| Mar 2022 | - | $113.91M(+243.0%) | $149.84M(-35.3%) |
| Dec 2021 | $231.68M(+81.4%) | $33.21M(+1275.8%) | $231.68M(+3.7%) |
| Sep 2021 | - | $2.41M(+696.7%) | $223.51M(+1.3%) |
| Jun 2021 | - | $303.00K(-99.8%) | $220.75M(-33.0%) |
| Mar 2021 | - | $195.75M(+681.8%) | $329.24M(+157.8%) |
| Dec 2020 | $127.71M(-6248.9%) | $25.04M(-7295.1%) | $127.71M(+24.3%) |
| Sep 2020 | - | -$348.00K(-100.3%) | $102.77M(+0.4%) |
| Jun 2020 | - | $108.80M(-1984.5%) | $102.38M(-1619.0%) |
| Mar 2020 | - | -$5.77M(-6176.8%) | -$6.74M(+224.5%) |
| Dec 2019 | -$2.08M(-100.9%) | $95.00K(-112.9%) | -$2.08M(+26.1%) |
| Sep 2019 | - | -$738.00K(+127.8%) | -$1.65M(-100.7%) |
| Jun 2019 | - | -$324.00K(-70.8%) | $230.05M(-1.5%) |
| Mar 2019 | - | -$1.11M(-311.4%) | $233.46M(+0.7%) |
| Dec 2018 | $231.86M | $525.00K(-99.8%) | $231.86M(-0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $230.96M(+7386.4%) | $232.70M(+2970.3%) |
| Jun 2018 | - | $3.08M(-214.2%) | $7.58M(+191.8%) |
| Mar 2018 | - | -$2.70M(-298.5%) | $2.60M(-52.3%) |
| Dec 2017 | $5.45M(-241.5%) | $1.36M(-76.7%) | $5.45M(-667.2%) |
| Sep 2017 | - | $5.83M(-407.6%) | -$960.00K(-65.2%) |
| Jun 2017 | - | -$1.90M(-1399.3%) | -$2.76M(-0.7%) |
| Mar 2017 | - | $146.00K(-102.9%) | -$2.78M(-27.9%) |
| Dec 2016 | -$3.85M(-103.8%) | -$5.04M(-224.9%) | -$3.85M(-258.6%) |
| Sep 2016 | - | $4.04M(-310.6%) | $2.43M(-105.8%) |
| Jun 2016 | - | -$1.92M(+107.0%) | -$41.72M(+7.8%) |
| Mar 2016 | - | -$926.00K(-175.2%) | -$38.70M(-138.1%) |
| Dec 2015 | $101.60M(+6.6%) | $1.23M(-103.1%) | $101.60M(+1.8%) |
| Sep 2015 | - | -$40.11M(-3726.7%) | $99.84M(-30.4%) |
| Jun 2015 | - | $1.11M(-99.2%) | $143.49M(-26.8%) |
| Mar 2015 | - | $139.38M(<-9900.0%) | $196.08M(+105.7%) |
| Dec 2014 | $95.32M(+228.9%) | -$533.00K(-115.0%) | $95.32M(-0.0%) |
| Sep 2014 | - | $3.54M(-93.4%) | $95.32M(-15.6%) |
| Jun 2014 | - | $53.69M(+39.0%) | $112.91M(+90.7%) |
| Mar 2014 | - | $38.62M(-7382.1%) | $59.22M(+104.3%) |
| Dec 2013 | $28.98M(+553.1%) | -$530.30K(-102.5%) | $28.98M(-1.8%) |
| Sep 2013 | - | $21.13M(>+9900.0%) | $29.51M(+252.3%) |
| Jun 2013 | - | $0.00(-100.0%) | $8.38M(0.0%) |
| Mar 2013 | - | $8.38M(>+9900.0%) | $8.38M(>+9900.0%) |
| Dec 2012 | $4.44M | - | - |
| Aug 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2010 | - | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Travere Therapeutics?
- What is Travere Therapeutics annual CFF year-on-year change?
- What is Travere Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Travere Therapeutics?
- What is Travere Therapeutics quarterly CFF year-on-year change?
- What is Travere Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Travere Therapeutics?
- What is Travere Therapeutics TTM CFF year-on-year change?
What is Travere Therapeutics annual cash flow from financing activities?
The current annual CFF of TVTX is $139.42M
What is the all time high annual CFF for Travere Therapeutics?
Travere Therapeutics all-time high annual cash flow from financing activities is $231.86M
What is Travere Therapeutics annual CFF year-on-year change?
Over the past year, TVTX annual cash flow from financing activities has changed by -$79.33M (-36.26%)
What is Travere Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TVTX is $3.72M
What is the all time high quarterly CFF for Travere Therapeutics?
Travere Therapeutics all-time high quarterly cash flow from financing activities is $230.96M
What is Travere Therapeutics quarterly CFF year-on-year change?
Over the past year, TVTX quarterly cash flow from financing activities has changed by +$4.24M (+808.19%)
What is Travere Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TVTX is $143.66M
What is the all time high TTM CFF for Travere Therapeutics?
Travere Therapeutics all-time high TTM cash flow from financing activities is $329.24M
What is Travere Therapeutics TTM CFF year-on-year change?
Over the past year, TVTX TTM cash flow from financing activities has changed by +$142.43M (+11570.59%)